Keywords: amgen, romiplostim, meets, phase, iii, endpoints, itp

Amgen's romiplostim meets Phase III endpoints in ITP

Article | 17 December 2007

Print This

US biotechnology giant Amgen says that data from a trial of its developmental drug romiplostim indicate that it increased and ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in